Human Papillomavirus Infection (HPV) Prevalence in the Black Sea Region of Turkey: Primary HPV Screening for Cervical Cancer

被引:1
作者
Dura, Mustafa Cengiz [1 ]
Akturk, Hilal [1 ]
Aslan, Ozgur [2 ]
Yildiz, Sukru [2 ]
Kefeli, Mehmet [3 ]
Celik, Handan [4 ]
机构
[1] Bakirkoy Sadi Konuk Educ & Res Hosp, Obstet & Gynaecol, Istanbul, Turkiye
[2] Bakirkoy Sadi Konuk Educ & Res Hosp, Obstet & Gynaecol, Istanbul, Turkiye
[3] Ondokuzmayis Univ, Fac Med, Dept Pathol, Samsun, Turkiye
[4] Ondokuzmayis Univ, Fac Med, Obstet & Gynecol, Samsun, Turkiye
关键词
cancer; cervical; co-test; smear; prevalence; hpv; MALE CIRCUMCISION; WOMEN;
D O I
10.7759/cureus.52615
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: Planning vaccination and treatment options requires knowledge about the regional incidence of human papillomavirus infection (HPV) and its genotypes. The aim of our study was to determine the regional prevalence of HPV with genotypic subclassification and to evaluate the efficacy of HPV testing in cervical screening. Material and Method: This retrospective cohort study analyzed records of 10,152 women aged 30-65 from the On Dokuz Mayis University Medical Faculty's Gynecology Clinic, excluding those with a history of cervical disease, hysterectomy, or current pregnancy. Pre- and postmenopausal and total HPV prevalence were calculated. There was a total of 544 patients who underwent a colposcopic biopsy after cervical screening. The research focused on comparing the efficacy of Pap smears, HPV tests, and co -tests in detecting LSIL or more severe conditions, utilizing the BD Viper LT System for HPV screening and liquidbased cytology for smear tests. Results: The prevalence of HPV in our region was determined to be 10.9%. When considering menopausal status, HPV prevalence was found to be 9.8% in premenopausal individuals and 12.4% in postmenopausal individuals. Evaluation of the pap smear results revealed a sensitivity of 74.8% for premenopausal and 81% for postmenopausal patients, with a specificity of 51% observed in both menopausal categories. In contrast, HPV testing demonstrated a sensitivity of 90.8% in premenopausal and 92.4% in postmenopausal individuals, with a specificity of 58% for both groups. The co -test results indicated an even higher sensitivity, with 97.9% in premenopausal and 100% in postmenopausal individuals, albeit with a reduced specificity of 28% in both cases. When identifying LSIL (low-grade squamous intraepithelial lesions) and more severe conditions, the sensitivity and specificity of the primary HPV test surpassed those of the pap smear. While the primary HPV test's sensitivity is markedly lower compared to the co -test, it boasts a significantly higher specificity. Conclusion: Regional HPV prevalence studies are valuable for the implementation of screening policies. The primary HPV DNA test is a reliable method for detecting preinvasive and invasive lesions in patients over 30 years of age.
引用
收藏
页数:8
相关论文
共 26 条
[1]  
Akturk H, 2023, SAGLIK & BILIM 2023 GUNCEL TIP-IV, P2
[2]   Clinical applications of HPV testing: A summary of meta-analyses [J].
Arbyn, Marc ;
Sasieni, Peter ;
Meijer, Chris J. L. M. ;
Clavel, Christine ;
Koliopoulos, George ;
Dillner, Joakim .
VACCINE, 2006, 24 :78-89
[3]   PHYLOGENETIC ANALYSIS AND PREVALENCE OF HUMAN PAPILLOMAVIRUS (HPV) IN WOMEN WITH SEVERAL CERVICAL PATHOLOGIES [J].
Avci, Gulcin Alp ;
Bozdayi, Gulendam ;
Taskiran, Cagatay ;
Ozkan, Secil ;
Onan, M. Anil .
TURKISH JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2013, 10 (03) :151-159
[4]   Comparison of cervical cancer screening results among 256,648 women in multiple clinical practices [J].
Blatt, Amy J. ;
Kennedy, Ronald ;
Luff, Ronald D. ;
Austin, R. Marshall ;
Rabin, Douglas S. .
CANCER CYTOPATHOLOGY, 2015, 123 (05) :282-288
[5]   PREVALENCE OF HUMAN PAPILLOMAVIRUS IN CERVICAL-CANCER - A WORLDWIDE PERSPECTIVE [J].
BOSCH, FX ;
MANOS, MM ;
MUNOZ, N ;
SHERMAN, M ;
JANSEN, AM ;
PETO, J ;
SCHIFFMAN, MH ;
MORENO, V ;
KURMAN, R ;
SHAH, KV ;
ALIHONOU, E ;
BAYO, S ;
MOKHTAR, HC ;
CHICAREON, S ;
DAUDT, A ;
DELOSRIOS, E ;
GHADIRIAN, P ;
KITINYA, JN ;
KOULIBALY, M ;
NGELANGEL, C ;
TINTORE, LMP ;
RIOSDALENZ, JL ;
SARJADI ;
SCHNEIDER, A ;
TAFUR, L ;
TEYSSIE, AR ;
ROLON, PA ;
TORROELLA, M ;
TAPIA, AV ;
WABINGA, HR ;
ZATONSKI, W ;
SYLLA, B ;
VIZCAINO, P ;
MAGNIN, D ;
KALDOR, J ;
GREER, C ;
WHEELER, C .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1995, 87 (11) :796-802
[6]   Population-based HPV vaccination programmes are safe and effective: 2017 update and the impetus for achieving better global coverage [J].
Brotherton, Julia M. L. ;
Bloem, Paul N. .
BEST PRACTICE & RESEARCH CLINICAL OBSTETRICS & GYNAECOLOGY, 2018, 47 :42-58
[7]   Male circumcision, penile human papillomavirus infection, and cervical cancer in female partners. [J].
Castellsague, X ;
Bosch, FX ;
Munoz, N ;
Meijer, CJLM ;
Shah, KV ;
de Sanjose, S ;
Eluf-Neto, J ;
Ngelangel, CA ;
Chichareon, S ;
Smith, JS ;
Herrero, R ;
Moreno, V ;
Franceschi, S .
NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (15) :1105-1112
[8]   Human Papillomavirus DNA Methylation as a Potential Biomarker for Cervical Cancer [J].
Clarke, Megan A. ;
Wentzensen, Nicolas ;
Mirabello, Lisa ;
Ghosh, Arpita ;
Wacholder, Sholom ;
Harari, Ariana ;
Lorincz, Attila ;
Schiffman, Mark ;
Burk, Robert D. .
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2012, 21 (12) :2125-2137
[9]   Comparison of cervical cancer screening strategies incorporating different combinations of cytology, HPV testing, and genotyping for HPV 16/18: results from the ATHENA HPV study [J].
Cox, J. Thomas ;
Castle, Phillip E. ;
Behrens, Catherine M. ;
Sharma, Abha ;
Wright, Thomas C., Jr. ;
Cuzick, Jack .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2013, 208 (03) :184.e1-184.e11
[10]   Human papillomavirus (HPV) prevalence and types among Turkish women at a gynecology outpatient unit [J].
Dursun, Polat ;
Senger, Sueheyla S. ;
Arslan, Hande ;
Kuscu, Esra ;
Ayhan, Ali .
BMC INFECTIOUS DISEASES, 2009, 9